CD8+ T,B

Hengqi Liu1, Yingfang Feng1,2, Zhengzi Qian1

  • 1State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine/Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, the Sino-US Center for Lymphoma and Leukemia Research, Tianjin, China.

Frontiers in immunology
|December 29, 2025
PubMed
概括

这项研究揭示了扩散性大B细胞淋巴瘤 (DLBCL) 中的CD8+T细胞异质性. 一种新的基因特征预测了患者的生存率和对CAR-T治疗的反应,提高了预后准确度.